These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Thrombophilia, thromboembolism and the use of the unfractionated and low-molecular-weight heparins]. Lobato-Mendizábal E; Majluf-Cruz A Rev Invest Clin; 2000; 52(5):529-45. PubMed ID: 11195182 [TBL] [Abstract][Full Text] [Related]
5. Heparins in the new millennium: will unfractionated heparin survive? Introduction. McClatchey KD; Galvin HM; Galvin RM Semin Thromb Hemost; 2000; 26 Suppl 1():3-4. PubMed ID: 11011801 [No Abstract] [Full Text] [Related]
7. The safety and usefulness of low molecular weight heparins and unfractionated heparins in patients with acute stroke. Kiphuth IC; Köhrmann M; Huttner HB; Schellinger PD Expert Opin Drug Saf; 2009 Sep; 8(5):585-97. PubMed ID: 19614560 [TBL] [Abstract][Full Text] [Related]
9. Is there enough evidence that low-molecular-weight heparin is superior to unfractionated heparin in pulmonary embolism? Sharma GK Arch Intern Med; 2000 Jul; 160(13):2065-6. PubMed ID: 10888989 [No Abstract] [Full Text] [Related]
10. The use of unfractionated heparin and low molecular weight heparins in pregnancy. Casele HL Clin Obstet Gynecol; 2006 Dec; 49(4):895-905. PubMed ID: 17082684 [TBL] [Abstract][Full Text] [Related]
11. Unfractionated heparin versus low-molecular-weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients. Ang E Clin Nurse Spec; 2013; 27(5):229-30. PubMed ID: 23942101 [No Abstract] [Full Text] [Related]
12. Are all low molecular weight heparins equivalent in the management of venous thromboembolism? Fareed J; Jeske W; Fareed D; Clark M; Wahi R; Adiguzel C; Hoppensteadt D Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137 [TBL] [Abstract][Full Text] [Related]
13. Management of thromboembolism in pregnancy. Marks PW Semin Perinatol; 2007 Aug; 31(4):227-31. PubMed ID: 17825678 [TBL] [Abstract][Full Text] [Related]
15. [Preventive and therapeutic anticoagulation in theory and practice: updates in thrombosis prevention]. Wilke S Pflege Z; 2009 Jul; 62(7):412-5. PubMed ID: 19634523 [No Abstract] [Full Text] [Related]
16. Unfractionated and low-molecular-weight heparin. Comparisons and current recommendations. Pineo GF; Hull RD Med Clin North Am; 1998 May; 82(3):587-99. PubMed ID: 9646781 [TBL] [Abstract][Full Text] [Related]
17. Role of heparin and low-molecular-weight heparins in the management of acute ischemic stroke. Padma V; Fisher M; Moonis M Expert Rev Cardiovasc Ther; 2006 May; 4(3):405-15. PubMed ID: 16716101 [TBL] [Abstract][Full Text] [Related]
18. Low molecular weight heparins as thromboprophylaxis in patients undergoing hemodialysis/hemofiltration or continuous renal replacement therapies. Sagedal S; Hartmann A Eur J Med Res; 2004 Mar; 9(3):125-30. PubMed ID: 15096322 [TBL] [Abstract][Full Text] [Related]
19. Effects of anticoagulants on cancer: heparins. Pineo GF; Hull RD Cancer Treat Res; 2009; 148():259-75. PubMed ID: 19377929 [No Abstract] [Full Text] [Related]
20. Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: the underestimated modifying effects of heparin. Borawski J Am J Kidney Dis; 2006 Jan; 47(1):37-41. PubMed ID: 16377383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]